An investigation for investors in Dr.Reddy’s Laboratories Ltd (ADR) (NYSE:RDY) shares over potential securities laws violations by Dr. Reddy’s Laboratories was announced.
San Diego, CA -- (SBWIRE) -- 08/14/2017 -- An investigation was announced for investors in (NYSE:RDY) shares over potential securities laws violations by Dr.Reddy's Laboratories Ltd and certain of its directors and officers.
Investors who purchased shares of Dr.Reddy's Laboratories Ltd (ADR) (NYSE:RDY), have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call 858-779-1554.
The investigation by a law firm focuses on whether a series of statements by Dr.Reddy's Laboratories Ltd regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On November 6, 2015, Dr.Reddy's Laboratories Ltd's announced that it had received a warning letter issued by the U.S. Food and Drug Administration ("FDA") concerning inadequate quality control standards at three of the Company's manufacturing plants in India.
On August 10, 2017, Dr.Reddy's Laboratories Ltd's disclosed that the Regulatory of Germany (Regierung von Oberbayern) did not renew the good manufacturing practices (GMP) compliance certificate of a formulations manufacturing unit of the Company's German subsidiary Betapharm Arzneimittel, located in Hyderabad, India, following a recent inspection of the plant.
Shares of Dr.Reddy's Laboratories Ltd (ADR) (NYSE:RDY) declined to as low as $30.22 per share on August 10, 2017.
Those who purchased shares of Dr.Reddy's Laboratories Ltd (ADR) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego